Asset Details
Do you wish to reserve the book?
Incidence and costs of hypoglycemia in insulin-treated diabetes in Switzerland: A health-economic analysis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Incidence and costs of hypoglycemia in insulin-treated diabetes in Switzerland: A health-economic analysis
Do you wish to request the book?
Incidence and costs of hypoglycemia in insulin-treated diabetes in Switzerland: A health-economic analysis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Incidence and costs of hypoglycemia in insulin-treated diabetes in Switzerland: A health-economic analysis
2023
Overview
We assess the incidence and economic burden of severe and non-severe hypoglycemia in insulin-treated diabetes type 1 and 2 patients in Switzerland.
We developed a health economic model to assess the incidence of hypoglycemia, the subsequent medical costs, and the production losses in insulin-treated diabetes patients. The model distinguishes between severity of hypoglycemia, type of diabetes, and type of medical care. We used survey data, health statistics, and health care utilization data extracted from primary studies.
The number of hypoglycemic events in 2017 was estimated at 1.3 million in type 1 diabetes patients and at 0.7 million in insulin-treated type 2 diabetes patients. The subsequent medical costs amount to 38 million Swiss Francs (CHF), 61 % of which occur in type 2 diabetes. Outpatient visits dominate costs in both types of diabetes. Total production losses due to hypoglycemia amount to CHF 11 million. Almost 80 % of medical costs and 39 % of production losses are due to non-severe hypoglycemia.
Hypoglycemia leads to substantial socio-economic burden in Switzerland. Greater attention to non-severe hypoglycemic events and to severe hypoglycemia in type 2 diabetes could have a major impact on reducing this burden.
•9 % of hypoglycemic events in insulin-treated diabetes required medical care.•Type 2 diabetes dominated the costs of hypoglycemic events.•Total cost of insulin-induced hypoglycemia amounted to 71 million Swiss Francs in 2017.•Non-severe hypoglycemia led to 81 % of medical costs and 42 % of production losses.
Publisher
Elsevier Inc,Elsevier Limited
